Anti-tumor necrosis factor therapies reduce serum macrophage inflammatory protein-1alpha in ankylosing spondylitis

J Rheumatol. 2010 May;37(5):1073-4. doi: 10.3899/jrheum.091469.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / blood
  • Arthritis, Rheumatoid / immunology
  • Arthritis, Rheumatoid / therapy
  • Chemokine CCL3 / blood*
  • Chemokine CCL3 / immunology
  • Humans
  • Severity of Illness Index
  • Spondylitis, Ankylosing / blood*
  • Spondylitis, Ankylosing / immunology
  • Spondylitis, Ankylosing / therapy*
  • Statistics, Nonparametric
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / immunology

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Chemokine CCL3
  • Tumor Necrosis Factor-alpha